# Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

> **NCT03476655** · — · COMPLETED · sponsor: **Johnson & Johnson Private Limited** · enrollment: 40 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03476655
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-28
- **Primary completion:** 2019-05-14
- **Final completion:** 2019-05-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03476655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03476655, "Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03476655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*